New Trends in Treatment for Major Depressive Disorder

Slides:

Advertisements

Similar presentations

Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.

Advertisements

Depression Measures Health Disparities Collaborative 2005.

1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.

Treatment for Adolescents With Depression Study (TADS)

Mood Disorders: Depression Chapter 12. Defined as a depressed mood or loss of interest that lasts at least 2 weeks & is accompanied by symptoms such as.

STAR*D Objectives Compare relative efficacy of different treatment options –Goal is REMISSION, not just “response” –Less than half of patients with depression.

Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)

1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.

Politis A, Theleritis C, Soldatos C, Psarros C, Papadimitriou GN

Pharmacological and Behavioral

New Horizons for SMA.

Major Depressive Disorder: Latest Clinical Update

Key Issues in Depression: Highlights From APA 2016

How the Latest Data in MDD Can Guide Treatment Decisions:

Primary Care Challenges in Depression - To Treat or Refer?

Major Depressive Disorder: Getting the Patient Back to Work

What Is Major Depressive Disorder (MDD)?

The Patient Journey to Remission in MDD: A Collaborative Approach

Chronic Rhinosinusitis

The HCV Revolution: Are You and Your Practice Ready?

Neurostimulation for the Management of Medication-Resistant Epilepsy

Please consider these data to be preliminary until they have been published in peer-reviewed journals.

Unmet Needs in Schizophrenia

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

The Mood Disorder Spectrum

What Would You Do in This Case of MDD?

IL-17 Inhibitors in the Management of Psoriatic Disease

Postpartum Depression

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Hyperhidrosis Is Burdensome!

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Therapeutic Approaches to the Management of EDS in OSA

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Novel Approaches in T1D Management

Pseudobulbar Affect or Psychiatric Condition?

Impactful Data in TD That Can Guide Treatment Decisions

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

New Data on Emerging Treatments for Psoriasis

What Is Bipolar Disorder?

Personalizing Management in the Care of Patients With Advanced Sarcoma

Program Overview. Major Depressive Disorder: The Challenging Patient and the Goal of Recovery.

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

Talking With Your Patients About Excessive Sweating

Advances in Immunotherapy for Peanut Allergy

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Tackling Schizophrenia With Your Patients

Scientific Update.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Proteasome Inhibitors and Patients

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Debates and Dilemmas, Part 1

The ABCs of Pharmacogenomics in Clinical Practice

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Case Studies in Locally Advanced Pancreatic Cancer

The Psychiatrist's Role in Tardive Dyskinesia

Peanut Allergy Immunotherapy

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

The Glutamate Pathway.

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

Widening the Options for Major Depressive Disorder

A New Era in Migraine Prevention

Presentation transcript:

New Trends in Treatment for Major Depressive Disorder

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Major Depressive Disorder

Lifetime Prevalence of a Major Depressive Episode

Biological Basis of MDD

Recognizing MDD: Guidelines and Diagnostic Criteria

Social and Environmental Risks Factors for Developing MDD

Importance of a Correct Diagnosis

Need to Consider Comorbidities When Making Treatment Decisions

Identifying Treatment-Resistant Depression

Questions to Consider While Participating in this Program

Recommendations and Tools For Assessing the Effect of Treatment for Major Depressive Disorder

Guidelines for the Treatment of MDD

Guidelines and Goals of Treatment

Early Improvement in the First 2 Weeks of Treatment Is Indicator of Later Response

Increase in Positive Mood at 2 Weeks is a Predictor of Positive Treatment Response

Clinicians May Appreciate Information From Scales but Seldom Use Them

Commonly Used Rating Scales for MDD

Patients' Expectations From Antidepressant Treatment

A Simple Approach to Assessment

Defining Treatment-Resistant Depression

Today's Approaches to Treatment for Major Depressive Disorder

The Mechanism of Action of Antidepressant Drugs: The Role of Monoamines

Systematic Review and Network Meta-Analysis of 21 Antidepressant Drugs for MDD: Efficacy Comparison

Primary Outcome Results for the Network Meta-Analysis: Acceptability

Remission Rates With Antidepressants Evaluated in STAR Remission Rates With Antidepressants Evaluated in STAR*D: According to Lines of Treatment

Treatment Strategies When First-Line Treatment Fails

Nonpharmacologic Approaches to MDD and TRD

Closing Remarks

Future Treatment Outlook: What's New or Around the Corner in Major Depressive Disorder?

Ketamine: Mechanism of Action

Opiate Involvement in Attenuating Antidepressant Effects of Ketamine

Intranasal Esketamine: Phase 3 Programme

Efficacy of Intranasal Esketamine in TRD: Randomized, Double-Blind Study

Continued Esketamine Plus Antidepressant: Delay in Relapse in Patients With TRD

Long-Term Efficacy and Safety of Esketamine Nasal Spray in TRD

Brexanolone Injection in Postpartum Depression: Phase 3 Trials

Other Compounds for MDD or TRD in Phase 2 or 3 Trials